Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $98.28 USD
Change Today +1.12 / 1.15%
Volume 1.6M
INCY On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 05/1/15 All times are local (Market data is delayed by at least 15 minutes).

incyte corp (INCY) Key Developments

Incyte Corporation Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015

Incyte Corporation reported unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, total revenue was $159.275 million against $89.792 million a year ago. Loss from operations was $6.935 million against $22.935 million a year ago. Loss before income taxes was $17.992 million against $33.908 million a year ago. Net loss was $18.359 million or $0.11 per basic and diluted share against $33.957 million or $0.21 per basic and diluted share a year ago.

Incyte Corporation to Report Q1, 2015 Results on Apr 30, 2015

Incyte Corporation announced that they will report Q1, 2015 results at 8:00 AM, US Eastern Standard Time on Apr 30, 2015

Incyte Corporation, Q1 2015 Earnings Call, Apr 30, 2015

Incyte Corporation, Q1 2015 Earnings Call, Apr 30, 2015

Incyte Corporation Establishes New Headquarters of Incyte Europe S.a.r.l in Geneva, Switzerland

Incyte Corporation announced that it will establish the new headquarters of Incyte Europe S.a.r.l in Geneva, Switzerland. The company intends to use Incyte Europe as the base from which it will conduct its European clinical development operations, and expects to occupy the 9,000 sq. ft. facility by mid-2015.

Incyte Corporation Appoints Steven H. Stein as Senior Vice President and Chief Medical Officer

Incyte Corporation announced that Steven H. Stein, MD, has been appointed Senior Vice President and Chief Medical Officer, effective immediately. Dr. Stein was formerly SVP, US Clinical Development & Medical Affairs at Novartis Oncology US, and he will be responsible for clinical and medical strategy and operations across Incyte’s extensive oncology portfolio. He will join the executive management team of Incyte, and report to Richard S. Levy, MD, Executive Vice President and Chief Drug Development Officer.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
INCY:US $98.28 USD +1.12

INCY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Alkermes PLC $59.10 USD +3.73
ARIAD Pharmaceuticals Inc $9.15 USD +0.48
BioMarin Pharmaceutical Inc $115.92 USD +3.87
Jazz Pharmaceuticals PLC $180.74 USD +2.04
Vertex Pharmaceuticals Inc $125.60 USD +2.32
View Industry Companies
 

Industry Analysis

INCY

Industry Average

Valuation INCY Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 29.1x
Price/Book -- Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact INCYTE CORP, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.